Related Experiment Video

Updated: Jun 19, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Adverse cutaneous reactions induced by TNF-alpha antagonist therapy

Joaquín Borrás-Blasco1, Andrés Navarro-Ruiz, Consuelo Borrás

  • 1Pharmacy Department, Hospital de Sagunto, Sagunto, Spain. jborrasb@gmail.com

Southern Medical Journal
|October 30, 2009
PubMed
Abstract

Insights

Tumor necrosis factor alpha (TNF-alpha) antagonist therapy is linked to increased skin reactions, including psoriasis and lupus-like syndromes. Clinicians must recognize and manage these adverse cutaneous drug reactions.

Area of Science:

  • Dermatology
  • Rheumatology
  • Immunology

Background:

  • Tumor necrosis factor alpha (TNF-alpha) antagonists are widely used for rheumatologic conditions.
  • Adverse cutaneous drug reactions (ACDRs) are potential side effects of TNF-alpha antagonist therapy.

Purpose of the Study:

  • To review ACDRs associated with TNF-alpha antagonist therapy.
  • To highlight the spectrum of skin lesions and management challenges.

Main Methods:

  • Comprehensive literature search of PubMed, EMBASE, and MEDLINE (1996-2009).
  • Inclusion of clinical trial data, case reports, letters, and review articles.

Main Results:

  • TNF-alpha antagonist use is associated with a significant increase in ACDRs.
  • Common reactions include new-onset or worsening psoriasis and lupus-like syndromes.
  • Rare but serious reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.

Conclusions:

  • The increasing use of TNF-alpha antagonists necessitates greater awareness of cutaneous side effects.
  • Diagnosis and management of skin conditions in patients on TNF-alpha antagonists present a growing clinical challenge.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...